Ryvu Therapeutics S.A. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was PLN 14.26 million compared to PLN 0.130898 million a year ago. Revenue was PLN 19.73 million compared to PLN 7 million a year ago. Net loss was PLN 11.8 million compared to PLN 22.82 million a year ago. Basic loss per share from continuing operations was PLN 0.643 compared to PLN 1.243 a year ago. Diluted loss per share from continuing operations was PLN 0.643 compared to PLN 1.243 a year ago.
For the nine months, sales was PLN 14.33 million compared to PLN 0.55508 million a year ago. Revenue was PLN 33.82 million compared to PLN 18.75 million a year ago. Net loss was PLN 75.26 million compared to PLN 60.63 million a year ago. Basic loss per share from continuing operations was PLN 4.1 compared to PLN 3.303 a year ago. Diluted loss per share from continuing operations was PLN 4.1 compared to PLN 3.303 a year ago.